Literature DB >> 29050501

Platelet Activation Assessed by Glycoprotein VI/Platelet Ratio Is Associated With Portal Vein Thrombosis After Hepatectomy and Splenectomy in Patients With Liver Cirrhosis.

Toshiki Matsui1, Masanobu Usui1, Hideo Wada2, Yusuke Iizawa1, Hiroyuki Kato1, Akihiro Tanemura1, Yasuhiro Murata1, Naohisa Kuriyama1, Masashi Kishiwada1, Shugo Mizuno1, Hiroyuki Sakurai1, Shuji Isaji1.   

Abstract

Portal vein thrombosis (PVT) is a serious complication after hepatobiliary-pancreatic surgery. Portal vein thrombosis often develops in patients with liver cirrhosis (LC) postoperatively, although they have low platelet counts. Platelet activation is one of the causes of thrombosis formation, and soluble form of glycoprotein VI (sGPVI) has received attention as a platelet activation marker. We had prospectively enrolled the 81 consecutive patients who underwent splenectomy (Sx) and/or hepatectomy: these patients were divided as Sx (n = 38) and hepatectomy (Hx, n = 46) groups. The 3 patients who underwent both procedures were added to both groups. Each group was subdivided into patients with non-LC and LC: non-LC-Sx (n = 22) and LC-Sx (n = 16), non-LC-Hx (n = 40) and LC-Hx (n = 6). The presence of PVT was diagnosed by using enhanced computed tomography (CT) scan. Platelet counts were significantly lower in LC-Sx than in non-LC-Sx, and incidence of PVT was significantly higher in LC-Sx than in non-LC-Sx (68.8% vs 31.8%, P = .024). Soluble form of glycoprotein VI /platelet ratios on preoperative day and postoperative day 1 were significantly higher in LC-Sx than in non-LC-Sx. Incidence of PVT was significantly higher in LC-Hx than in non-LC-Hx (50.0% vs 7.5%, P < .01). Soluble form of glycoprotein VI /platelet ratios were significantly higher in LC-Hx before and after Hx, compared to non-LC-Hx. Patients with LC stay in hypercoagulable state together with platelet activation before and after surgery. Under this circumstance, alteration of portal venous blood flow after Sx or Hx is likely to cause PVT in patients with LC.

Entities:  

Keywords:  glycoprotein VI; hepatobiliary-pancreatic surgery; portal vein thrombosis

Mesh:

Substances:

Year:  2017        PMID: 29050501      PMCID: PMC6714669          DOI: 10.1177/1076029617725600

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  4 in total

1.  Splanchnic Vein Thrombosis in Liver Cirrhosis After Splenectomy or Splenic Artery Embolization: A Systematic Review and Meta-Analysis.

Authors:  Yanyan Wu; Hongyu Li; Tiansong Zhang; Zhaohui Bai; Xiangbo Xu; Giovanni Battista Levi Sandri; Le Wang; Xingshun Qi
Journal:  Adv Ther       Date:  2021-03-09       Impact factor: 3.845

2.  Treatment of acute exacerbation of liver-cirrhosis-associated portal vein thrombosis with direct-acting oral anticoagulant, edoxaban, used as an initial treatment in the early postoperative period after abdominal surgery: a case report.

Authors:  Junya Toyoda; Daisuke Morioka; Nobutoshi Horii; Gakuryu Nakayama; Norio Oyama; Fumio Asano; Yusuke Izumisawa; Masaru Miura; Yoshiki Sato; Itaru Endo
Journal:  J Med Case Rep       Date:  2021-02-10

3.  Machine learning predicts portal vein thrombosis after splenectomy in patients with portal hypertension: Comparative analysis of three practical models.

Authors:  Jian Li; Qi-Qi Wu; Rong-Hua Zhu; Xing Lv; Wen-Qiang Wang; Jin-Lin Wang; Bin-Yong Liang; Zhi-Yong Huang; Er-Lei Zhang
Journal:  World J Gastroenterol       Date:  2022-08-28       Impact factor: 5.374

4.  Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt.

Authors:  Chongtu Yang; Jiacheng Liu; Qin Shi; Songjiang Huang; Chen Zhou; Yingliang Wang; Tongqiang Li; Yang Chen; Bin Xiong
Journal:  J Gastroenterol Hepatol       Date:  2021-05-20       Impact factor: 4.029

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.